What is claimed is:
1. An isolated cDNA comprising a nucleic acid sequence encoding a protein having the amino acid sequence of SEQ ID NO:1, or the complement thereof.
2. An isolated cDNA comprising a nucleic acid sequence selected from:
a) SEQ ID NO:2 or the complement thereof;
b) a fragment of SEQ ID NO:2 selected from SEQ ID NOs:3-5 or the complement thereof; and
c) a variant of SEQ ID NO:2 selected from SEQ ID NOs:6-11 or the complement thereof.
3. A composition comprising the cDNA or the complement of the cDNA of claim 1 and a labeling moiety.
4. A vector comprising the cDNA of claim 1.
5. A host cell comprising the vector of claim 4.
6. A method for using a cDNA to produce a protein, the method comprising:
a) culturing the host cell of claim 5 under conditions for protein expression; and
b) recovering the protein from the host cell culture.
7. A method for using a cDNA to detect expression of a nucleic acid in a sample comprising:
a) hybridizing the composition of claim 3 to nucleic acids of the sample, thereby forming hybridization complexes; and
b) comparing hybridization complex formation with a standard, wherein the comparison indicates expression of the cDNA in the sample.
8. The method of claim 7 further comprising amplifying the nucleic acids of the sample prior to hybridization.
9. The method of claim 7 wherein the composition is attached to a substrate.
10. The method of claim 7 wherein the cDNA is differentially expressed when compared with a standard and diagnostic of breast cancer, ovarian cancer, kidney cancer, Mohr-Tranebjaerg syndrome, epilepsy, spasticity, or dystonia.
11. A method of using a cDNA to screen a plurality of molecules or compounds, the method comprising:
a) combining the cDNA of claim 1 with a plurality of molecules or compounds under conditions to allow specific binding; and
b) detecting specific binding, thereby identifying a molecule or compound which specifically binds the cDNA.
12. The method of claim 11 wherein the molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acids, artificial chromosome constructions, peptides, transcription factors, repressors, and regulatory molecules.
13. A purified protein or a portion thereof produced by the method of claim 6 and selected from:
a) an amino acid sequence of SEQ ID NO:1;
b) an antigenic epitope of SEQ ID NO:1; and
c) a biologically active portion of SEQ ID NO:1.
14. A composition comprising the protein of claim 13 and a pharmaceutical carrier.
15. A method for using a protein to screen a plurality of molecules or compounds to identify at least one ligand, the method comprising:
a) combining the protein of claim 13 with the molecules or compounds under conditions to allow specific binding; and
b) detecting specific binding, thereby identifying a ligand which specifically binds the protein.
16. The method of claim 15 wherein the molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acids, peptides, proteins, mimetics, agonists, antagonists, antibodies, immunoglobulins, inhibitors, and drugs.
17. A method of using a protein to prepare and purify antibodies comprising:
a) immunizing a animal with the protein of claim 15 under conditions to elicit an antibody response;
b) isolating animal antibodies;
c) attaching the protein to a substrate;
d) contacting the substrate with isolated antibodies under conditions to allow specific binding to the protein;
e) dissociating the antibodies from the protein, thereby obtaining purified antibodies.
18. An antibody produced by the method of claim 17.
19. A method for using an antibody to diagnose a disease or condition associated with expression of a protein, the method comprising:
a) combining the antibody of claim 18 with a sample, thereby forming antibody:protein complexes; and
b) comparing complex formation with a standard, wherein the comparison indicates expression of the protein in the sample.
20. The method of claim 19 wherein the disease or condition is selected from breast cancer, ovarian cancer, kidney cancer, Mohr-Tranebjaerg syndrome, epilepsy, spasticity, and dystonia.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A system for remotely controlling pressure within each of i zones respectively connectable to i measurement chambers through conduits i, by controlling flow of a fluid into and out of each measurement chamber i, and through each conduit i into each zone i, wherein i=1, . . . , N, the system comprising:
a plurality of measurement chambers, i, wherein each measurement chamber is controllably closable by operation of an inlet proportional valve and outlet proportional valve connected to the measurement chamber, wherein each outlet proportional valve is connected to a vacuum exhaust, and wherein the plurality of measurement chambers, i, are connected to one another at the respective outputs of the proportional valves by a flow constrictor manifold;
a plurality of zones i, wherein each zone is connected to a respective measurement chamber through a respective conduit, wherein each zone is a remote zone relative to the respective measurement chamber;
a pressure measurement system configured to measure pressure of the fluid in each of the i measurement chambers;
a valve system including, for each measurement chamber i, at least one inlet proportional valve configured to regulate an input flow rate of the fluid into the measurement chamber i, and at least one outlet proportional valve configured to regulate an output flow rate of the fluid out of the measurement chamber i;
a zone pressure estimator coupled to the pressure measurement system and configured to, for each zone i, receive a measured pressure in the measurement chamber i from the pressure measurement system, and compute an estimated pressure within the zone i as a function of the measured pressure in the measurement chamber i, and as a function of known characteristics of the conduit i and the zone i; and
a controller configured to control pressure within each zone i by operating the inlet proportional valve and the outlet proportional valve of each measurement chamber i so as to control the input flow rate of the fluid into the measurement chamber i and the outlet flow rate of the fluid out of the measurement chamber i as a function of a pressure set point for the zone i and the estimated pressure within the zone i from the zone pressure estimator,
wherein the controller is further configured to, for each zone, effect PI (Proportional-Integral) control of the input flow rate and the output flow rate;
wherein the pressure measurement system comprises a plurality of pressure sensors, each of the pressure sensors respectively connected to measure pressure within the i measurement chambers;
wherein at least some of the i zones have flexible walls that allow the zones having the flexible walls to expand and to contract,
wherein at least some of the i zones are coupled, and
wherein the known characteristics of the i conduits include constants Ctube,i and \u03c4tube,i associated with each conduit i connecting the line i to the zone i, Ctube,i representing a conductance of the conduit, and \u03c4tube,i representing a flow equilibration time constant across the conduit; and
wherein the known characteristics of the i zones include an initial volume (Vz0,i) of each zone i under STP (Standard Temperature and Pressure) conditions, a volume expansioncontraction time constant (\u03c4v), an expansioncontraction coefficient (\u03b3ii) of zone i, and a coupling coefficient (\u03b3ij) between zone i and zone j, where j=1, . . . , N.
2. The system of claim 1, wherein the zone pressure estimator is further configured to compute an estimated volume of each of the zones with flexible walls so as to compute the estimated pressure within enclosures that are connected to the zones with flexible walls.
3. The system of claim 1, wherein at least some of the i zones are coupled.
4. The system of claim 1, wherein for each zone i, the zone pressure estimator is programmed to calculate an nth sample {circumflex over (P)}z,i(n) of the estimated pressure of the zone i, an nth sample {circumflex over (V)}z,i(n) of an estimated volume of the zone i, and an nth sample {circumflex over (Q)}z,i(n) of an estimated input flow rate into an enclosure i;
and wherein
P
^
z
,
i
(
n
)
=
P
^
z
,
i
(
n
–
1
)
+
\u0394
\u2062
\u2062
t
\u2061
(
P
STP
V
^
z
,
i
(
n
)
\u2062
Q
^
z
,
i
(
n
)
+
P
^
z
,
i
(
n
–
1
)
\u03c4
v
\u2062
V
^
z
,
i
(
n
)
\u2062
\u2003
V
^
z
,
i
(
n
)
–
V
z
\u2062
\u2062
0
,
i
–
\u03b3
ii
\u2062
(
P
^
z
,
i
(
n
–
1
)
–
P
STP
)
–
\u2211
i
\u2260
j
\u2062
\u2062
\u03b3
ij
\u2061
(
P
^
z
,
i
(
n
–
1
)
–
P
^
i
,
j
(
n
–
1
)
)
)
,
\u2062
\u2062
Q
^
z
,
i
(
n
)
=
Q
^
z
,
i
(
n
–
1
)
+
\u0394
\u2062
\u2062
tC
pipe
,
i
\u2061
(
P
b
,
i
(
n
)
–
P
^
z
,
i
(
n
–
1
)
)
(
1
+
\u0394
\u2062
\u2062
t
\u03c4
pipe
,
i
)
,
\u2062
V
^
z
,
i
(
n
)
=
V
^
z
,
i
(
n
–
1
)
+
\u0394
\u2062
\u2062
t
\u03c4
v
\u2061
V
z
\u2062
\u2062
0
,
i
+
\u03b3
ii
\u2061
(
P
^
z
,
i
(
n
–
1
)
–
P
STP
)
+
\u2211
i
\u2260
j
\u2062
\u2062
\u03b3
ij
\u2061
(
P
^
z
,
i
(
n
–
1
)
–
P
^
z
,
j
(
n
–
1
)
)
(
1
+
\u0394
\u2062
\u2062
t
\u03c4
v
)
,
\u2062
\u2062
and
wherein Pbi denotes the pressure measured by the pressure sensor connected to enclosure i, wherein Qzi denotes an input flow rate of the fluid into zone i that is given by a different between the input flow rate Qin,i of the fluid into enclosure i and the output flow rate Qout,i of the fluid out of enclosure i.
5. A machine including the system of claim 4, and further including the i zones respectively connected to i enclosures.
6. The machine of claim 4, further comprising a CMP carrier head containing the i zones.